摘要
目的:评价复方苦参注射液联合化疗治疗晚期胃癌的疗效、KPS评分及对T细胞亚群的作用。方法:将90例晚期胃癌患者随机分为治疗组(复方苦参注射液+化疗组)和对照组(化疗组)。对照组应用多西他赛、奥沙利铂、氟尿嘧啶联合化疗,治疗组同时加用复方苦参注射液20ml/d静滴,连用2周,3周为一周期。结果:治疗组临床获益率(CR+PR+SD)77.08%,明显优于对照组为(61.90%)(P=0.029);治疗组、对照组Kamofsky评分提高率分别为60.4%和42.9%,两组对比有显著性差异(P=0.024);治疗组CD4及CD8阳性细胞的百分率分别是39.2±1.9和26.5±1.4,对照组分别是30.8±1.7和23.0±1.8,治疗组高于对照组(P=0.000)。结论:复方苦参注射液联合化疗治疗晚期胃癌有改善生活质量,提高免疫功能,增强化疗效果的作用。
Objective: To evaluate the effective of treating advanced gastric cancer with Fufangkushen injection plus chemotherapy, KPS (scores of quality of life) and T cell subsets. Methods: 90 cases of advanced gastric cancer are randomly divide in treatment group (Fufangkushen injection+chemotherapy) and control group (chemotherapy). control group were treated with joint chemotherapy of doceta -xel, oxaliplatin, fluorouracil, treatment group bases on joint chemotherapy add to Fufangkushen injection (20ml/d,d1-14), used 2 weeks, 3 weeks are one treatment. Results: Treatment group clinical benefit rate (CR+PR+SD) is 77.08%, is better than control group (61.90%) ( P=0.029); Karnofsky score increased rate of treatment group and control group are 60.4%, 42.9%, two groups have significant defference (P=0.024); treatment group positive cells rate of CD4 and CD8 are 39.2±1.9 and 26.5±1.4, control group are 30.8±1.7and 23.0il.8, treatment group is higher than control group (P=0.000). Conclusion: Treating advanced gastric cancer with Fufangkushen injection plus chemotherapy can improve quality of life, immune function, enhance the effect of chemotherapy.
出处
《中医临床研究》
2010年第23期63-64,共2页
Clinical Journal Of Chinese Medicine